

You may be eligible to participate in the AVT001 trial if you:

- Were diagnosed with Type 1
 Diabetes within the last 12
 months
- Are age 18 or older
- Are not pregnant,
 breastfeeding, or planning
 to become pregnant during
 the duration of the trial





Study sponsor: Avotres, Inc.



For more information or to schedule an appointment, please call: (888) 813-8669

Or email us at: T1DTrials@joslin.harvard.edu



Joslin Diabetes Center One Joslin Place Boston, MA 02215 Were you recently diagnosed with Type 1 Diabetes?





AVT001 Cell-Based Therapy in Type 1 Diabetes

Why are we doing this trial?

Most people with Type 1 Diabetes have a measurable problem with a group of immune regulatory cells.

Our goal is to determine if we can safely correct this immune regulatory problem and reduce the immune system's attack on the insulin-producing beta cells.



The Approach


Your own blood cells will be used to develop a treatment specific to you.

The AVT001 trial is randomized. Two thirds of participants will be assigned to receive the active treatment, and one third will receive an inactive placebo. You will not know which group you are in.

Procedures include examinations, cell collection, treatment infusions, mixed meal tolerance tests to monitor beta cell function, and other blood tests.

Follow up assessments will evaluate if treatment corrects the immune defect and preserves beta cell function.

00000000000000



Approximate 2 Year Commitment